Given the significant role of IL-17A in the homeostasis of the intestinal mucosa and the potential risk of infectious colitis and new-onset IBD under IL-17A-inhibitor therapy, it is crucial for healthcare providers to carefully select patients for this treatment and inform them about the potential side effects. Here, IL17A is linked to inflammatory bowel disease.